Barinthus Biotherapeutics plc (BRNS)

Market Cap	53.08M
Revenue (ttm)	14.97M
Net Income (ttm)	-69.43M
Shares Out	40.83M
EPS (ttm)	-1.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,088
Open	1.300
Previous Close	1.270
Day's Range	1.249 - 1.341
52-Week Range	0.640 - 2.920
Beta	-0.70
Analysts	Strong Buy
Price Target	3.00 (+130.77%)
Earnings Date	Nov 6, 2025

About BRNS

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunothe...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: BRNS
• Website: https://www.barinthusbio.com

Financial Performance

In 2024, Barinthus Biotherapeutics's revenue was $14.97 million, an increase of 1766.46% compared to the previous year's $802,000. Losses were -$61.07 million, -16.73% less than in 2023.

Analyst Summary

According to one analyst, the rating for BRNS stock is "Strong Buy" and the 12-month stock price target is $3.0.

Price Target

$3.0

(130.77% upside)

Analyst Consensus: Strong Buy